Claris Bio is a late-stage therapeutics company dedicated to advancing transformative therapies for sight-threatening conditions where no or limited treatment options exist.
With an initial focus on limbal stem cell deficiency (LSCD), a blinding disease, we are developing the first pharmacologic treatment approach for these patients to shift the paradigm from palliative care to meaningful improvements in vision and ocular surface health. Our near-term plan is to advance our lead therapeutic candidate, CSB-001 (oremepermin alfa ophthalmic solution), into LSCD pivotal studies in the first half of 2027, with a longer-term goal to become a leader in developing new therapies that improve vision and change patients’ lives.